Business Context and Reporting Period
Company: BioCardia, Inc. (BCDA)
Filing Type: Form 10-Q (Unaudited)
Period Ended: September 30, 2024
Business Overview: BioCardia is a clinical-stage company developing cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Key programs include the CardiAMP autologous cell therapy for heart failure and chronic myocardial ischemia, and the CardiALLO allogeneic mesenchymal stem cell therapy. The company also partners on its Helix biotherapeutic delivery system and commercializes Morph access devices.
Key Financial Metrics
| Metric (in thousands) | Q3 2024 | Q3 2023 | 9M 2024 | 9M 2023 |
|---|---|---|---|---|
| Revenue | $0 | $357 | $58 | $464 |
| Net Loss | $(1,737) | $(2,574) | $(5,650) | $(9,499) |
| Net Loss Per Share (Basic/Diluted) | $(0.61) | $(1.79) | $(2.65) | $(6.87) |
| Cash and Cash Equivalents (End of Period) | $4,930 | $1,835 | $4,930 | $1,835 |
| Accumulated Deficit | $(157,825) | $(150,103) | $(157,825) | $(150,103) |
| Operating Cash Flow (9M) | $(5,453) | $(8,123) | $(5,453) | $(8,123) |
| Financing Cash Flow (9M) | $9,285 | $2,607 | $9,285 | $2,607 |
Debt and Liquidity: The company has no senior debt listed on the balance sheet. Total liabilities were $3.5 million as of September 30, 2024, primarily consisting of operating lease liabilities and accrued expenses. Stockholders' equity turned positive to $2.8 million following recent capital raises.
Material Changes vs. Prior Period
- Revenue Decline: Collaboration revenue dropped to $0 in Q3 2024 from $357,000 in Q3 2023, and to $58,000 for the nine months ended Sept 30, 2024, compared to $464,000 in the prior year period. This reflects the variable nature of partner-driven development milestones.
- Expense Reduction: Total costs and expenses decreased significantly. R&D expenses fell to $931,000 in Q3 2024 from $1.9 million in Q3 2023, and SG&A expenses dropped to $825,000 from $1.1 million. Management attributes this to reduced personnel and clinical costs following the completion of enrollment in the CardiAMP Heart Failure Trial.
- Capital Raising: The company executed a significant public offering in September 2024, raising gross proceeds of $7.2 million. Additionally, $2.4 million was raised via At-The-Market (ATM) offerings during the nine-month period. This contrasts with the prior year where financing was more modest.
- Reverse Stock Split: A 1-for-15 reverse stock split was effected on May 30, 2024. All share and per-share data in the filing have been retroactively adjusted.
Outlook, Risks, and Management Commentary
Guidance and Outlook
Management does not provide specific financial guidance but outlines key operational milestones:
- CardiAMP Heart Failure Trial: Top-line data release is expected in Q1 2025. The company intends to request an FDA meeting regarding approvability.
- CardiAMP Chronic Myocardial Ischemia Trial: Top-line results for the roll-in cohort are expected in Q1 2025.
- CardiALLO Allogeneic Trial: The low-dose cohort is expected to complete in Q4 2024.
- Commercialization: New Morph-DNA products received FDA clearance in August 2024, with first commercial devices expected in November 2024.
Liquidity and Going Concern
Substantial Doubt: The filing explicitly states there is substantial doubt about the company's ability to continue as a going concern beyond one year from the date of issuance. With cash of approximately $4.9 million, management believes funds are insufficient to meet obligations beyond the second quarter of 2025 without additional financing.
Risks and Contingencies
- Capital Requirements: Future operations depend on raising additional capital through equity, debt, or partnerships. Failure to secure funding could force the company to reduce expenses, delay trials, or cease operations.
- Regulatory Risk: Success depends on FDA and PMDA approvals for cell therapy candidates, which are not guaranteed.
- Nasdaq Listing: The company previously faced compliance issues with Nasdaq listing requirements (minimum bid price and market value) but has regained compliance. Future non-compliance could lead to delisting.
- Concentration Risk: Approximately 99% of cash and cash equivalents are held by one financial institution, with amounts exceeding FDIC insurance limits.
Investor Verification Checklist
- Cash Runway: Verify the timeline for the next capital raise given the "substantial doubt" disclosure regarding liquidity beyond Q2 2025.
- Clinical Data Release: Monitor the Q1 2025 data release for the CardiAMP Heart Failure Trial, which is critical for regulatory approval and future valuation.
- Dilution Impact: Review the terms of the September 2024 offering (2.4 million shares issued plus warrants) and the remaining capacity under the new ATM agreement ($264,000 available).
- Revenue Sustainability: Assess the likelihood of recurring revenue from the Helix delivery partnerships given the current $0 revenue quarter.
- Share Count: Note the significant increase in outstanding shares (from ~1.58 million at year-end 2023 to ~4.52 million at Sept 30, 2024) due to the reverse split and new issuances.